Israel Englander’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Israel Englander’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,435	Closed	-$584K	–	6862
2020 Q4	$584K	Buy	+4,435	New	+$392K	﹤0.01%	4080
2020 Q3	–	Sell	-40,787	Closed	-$1.94M	–	5006
2020 Q2	$1.94M	Buy	+40,787	New	+$1.9M	﹤0.01%	2560
2019 Q3	–	Sell	-21,110	Closed	-$656K	–	4723
2019 Q2	$656K	Buy	21,110 +8,133	+63%	+$220K	﹤0.01%	3058
2019 Q1	$304K	Buy	+12,977	New	+$208K	﹤0.01%	3538
2018 Q3	–	Sell	-280,469	Closed	-$5.71M	–	4451
2018 Q2	$5.71M	Buy	+280,469	New	+$5.88M	0.01%	1724

Israel Englander's EIDX Position: Q1 2021 in Review

Israel Englander sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 4,435 shares — an estimated $584K sold.

Israel Englander first reported a position in EIDX in Q2 2018 and held it in 5 quarters. The position peaked at $5.71M in Q2 2018. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Israel Englander reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Israel Englander sold 4,435 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $584K.
Israel Englander first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 5 quarters.
Israel Englander's Eidos Therapeutics, Inc. Common Stock position peaked at $5.71M in Q2 2018.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Millennium Management's 13F filing for Q1 2021, filed 17 May 2021.